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The development of a second haematological disease during the course of systemic mastocytosis is a well-known phenomenon.
In most of the cases, they consist of myelodysplasia or myeloproliferative disorders. The association with lymphoproliferative
disorders has also been described, but it is uncommon and the relationship is not well established. We report a patient diagnosed
with systemic mastocytosis who three years later developed a splenic marginal zone lymphoma with villous lymphocytes.
1.Introduction
The term mastocytosis refers to a group of disorders charac-
terized by and abnormal growth and accumulation of mast
cells in one or more organs, including skin, lymph nodes,
bone marrow, nervous system, gastrointestinal tract, spleen,
and liver.
Systemic mastocytosis associated with clonal haemato-
logical nonmast cell lineage disease (SM-AHNMD) is an
entity recognized by the World Health Organization classi-
ﬁcation of tumours of hematopoietic tissues [1].
The occurrence of myeloproliferative syndromes in
patients with systemic mastocytosis is a well-recognized
phenomenon. However, non-Hodgkin’s lymphoma is very
uncommon.
We report a patient with urticaria pigmetosa of ten years
evolution and systemic mastocytosis (SM) diagnosed three
years ago who developed splenic marginal zone lymphoma
with villous lymphocytes, a low-grade B-cell non-Hodgkin’s
lymphoma characterized by splenomegaly, moderate lym-
phocytosis, bone marrow inﬁltration, serum monoclonal
band, and a benign course with response to splenectomy [2].
To our knowledge, the association of this neoplasm with SM
has not been previously documented in the literature.
2.CaseReport
A 65-year-old female with unremarkable past medical his-
tory presented with papular, purplish, and itchy cutaneous
lesions located on her forearms, thighs, and trunk for ten
years (Figure 1).
Laboratory investigations, including blood counts,
chemistry, and routine coagulation parameters, showed no
alterations. A skin biopsy from a papular lesion revealed
an acanthotic epidermis and hyperpigmentation of the
epidermal basal cell layer. Giemsa stain showed many mast
cells around blood vessels and scattered throughout the
dermis.
A bone marrow smear showed atypical large, spindle-
shaped, and hypogranulated mast cells with elongated
nucleus. The histological examination of a bone marrow
biopsy disclosed decreased cellularity and multifocal inﬁl-
trates of cells with oval nucleus and large cytoplasm. These
cells were positive with the monoclonal mast cell stain2 Dermatology Research and Practice
Figure 1: Papular, purplish cutaneous lesions of urticaria pigmen-
tosa on the forearms.
and located surrounding blood vessels or with interstitial
distribution. Surrounding these cells, small lymphocytic
aggregates were observed.
According to the cutaneous ﬁndings and the bone mar-
row inﬁltration, the diagnosis of systemic mastocytosis was
made.
Because of a moderate pruritus, the patient was treated
with H1-receptor blocking agents.
Three years later, a routine laboratory examination
showed anaemia, lymphocytosis, increased β2-microglobu-
lin (2.54mg/l, normal value: 1.5–2.3), and a serum mon-
oclonal band of lambda light chains. Physical examination
showed hepatosplenomegaly and lymphadenopathy, which
was conﬁrmed by an abdominal echography.
Peripheral blood smear showed morphologically abnor-
mal lymphocytes with elongated cytoplasmic extensions
(Figure 2). Immunohistochemical studies disclosed a B
immunophenotypecharacterizedbytheexpressionofCD22,
FMC7, CD20, and slight expression of CD11c, CD10, CD38,
and negative for CD5 and CD23.
A new bone marrow biopsy showed nodular inﬁltration
by atypical mast cells and nodular interstitial inﬁltration by
lymphoid cells positive with CD 20 stain (Figure 3).
These features were consistent with the diagnosis of
splenic marginal zone lymphoma with villous lymphocytes.
Thus, the diagnosis of systemic mastocytosis with coexisting
splenic marginal zone lymphoma with villous lymphocytes
was established.
She received chemotherapy with chlorambucil for 28
months with progressive improvement of laboratory test and
parallel clearing of trunk cutaneous lesions, but not on the
forearms and thighs. Two new skin biopsies of persistent
lesions and cleared skin showed similar number of mast cells
in both.
3. Discussion
A signiﬁcant number of patients with systemic mastocytosis
(5–40%) may develop an associated haematological clonal
nonmast cell lineage disease (SM-AHNMD). Both neo-
plasms are usually synchronously diagnosed on the basis of
Figure 2: Peripheral blood smear showing an atypical lymphocyte
with elongated cytoplasm processes.
morphologicalevaluationofabonemarrowbiopsy,although
laterdevelopmentofAHNMDinpatientswithlongstanding
mastocytosis, as in our patient, is also possible [3].
Any type of haematological malignancy may be associ-
ated with SM. However, myeloid neoplasms develop with
a much higher frequency than lymphoid neoplasms [4, 5].
Among 138 cases of SM-AHNMD reported by Pardanani et
al., 123 (89%) had associated myeloid neoplasm and only 7
(5%) had lymphoma [6].
The pathophysiologic basis of simultaneous occurrence
of SM and other neoplasms is not completely understood.
In the case of myeloid neoplasms, the ﬁrst possibility is
that a hematopoietic progenitor cell, capable of given rise
to mast cells and other myeloid cells, is involved. In this
case,twoclinicallydistinctdisordersdevelopduetosubclone
formation [7]. It has also been suggested that mast cells
may produce growth factors capable of stimulating the
proliferation of other cell lines [8, 9].
The codevelopment of SM and lymphoid malignancies,
due to the small number of cases reported, may be incidental
or may occur as a result of genetic instability.
Kim et al. demonstrated distinct clonal origins in mas-
tocytosis and associated B-cell lymphomas [10]. However,
there is evidence suggesting that B cells share a common
progenitor with macrophages, a cell lineage that appears
to be closely related to mastocytes, and c-Kit mutations
have been detected in B lymphocytes, apart from neoplastic
mastocytes, so the same origin of both neoplasm is another
possibility [11].
Patients with SM and lymphoproliferative diseases usu-
ally have a long history of indolent SM, which suggests a
diﬀerent pathogenesis for the two entities. In our case, NHL
developed three years after the diagnosis of SM in a patient
with urticaria pigmentosa of ten years evolution.
Treatment and prognosis of SM-AHNMD depend on
theassociatedhaematologicaldisease.Chemotherapyusually
aﬀects the associated haematological neoplasm with little
or no eﬀect on mast cell disease [12, 13]. In our patient,
improvementofcutaneouslesionsonthetrunkwasobserved
after treatment with chlorambucil, but histological exam-
ination showed no decrease in the number of mast cells.
The signiﬁcance of this fact is not well understood, and itDermatology Research and Practice 3
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Figure 3: (a) Bone marrow biopsy with areas of inﬁltration by
villouslymphocytes(2arrows)andareasofinﬁltrationbymastcells
and ﬁbrosis (arrow) (haematoxylin-eosin, original magniﬁcation
×200). (b) Areas of mast cell inﬁltration in the bone marrow (Mast
cellstain ×150).(c)Villouslymphocytesinthebonemarrow(CD20
stain ×150).
might be associated with a poor prognosis in patients with
associated hematologic disorders [14]. It is believed that it
may be a natural process in the evolution of SM or could be
related with a change in homing receptor mast cells.
4. Conclusion
In summary, we report a case of SM-AHNMD, with the
peculiarity that the associated neoplasm was a splenic
marginal zone lymphoma, an association of which we have
found no previous reports in the literature.
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